The establishment and maintenance of the vascular system is critical for embryonic development
and postnatal life. Defects in endothelial cell development and vessel formation and …

Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has also …

Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …

PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell
lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …

Background Immunotherapy combination treatments can improve patient outcomes. Epacadostat,
an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

Background Effective treatments are needed to improve outcomes for high-grade glioma and
low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in …

Background Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which
has shown robust anti-tumour efficacy, along with intracranial activity, in patients with ALK-…

Microsatellite instability (MSI) refers to the hypermutability of short repetitive sequences in
the genome caused by impaired DNA mismatch repair. Although MSI has been studied for …

PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging,
bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. Single-…